Transcatheter aortic valve replacement in patients with quadricuspid aortic valve in a single center

Yang Liu, Mengen Zhai, Yu Mao, Chennian Xu, Yanyan Ma, Lanlan Li, Ping Jin, Jian Yang, Yang Liu, Mengen Zhai, Yu Mao, Chennian Xu, Yanyan Ma, Lanlan Li, Ping Jin, Jian Yang

Abstract

Background: Quadricuspid aortic valve (QAV) is a rare congenital malformation that can present with aortic regurgitation or aortic stenosis (AS)), requiring surgical treatment. Transcatheter aortic valve replacement (TAVR) is an alternative treatment for older patients and its prognosis for QAV therapy remains challenging. We sought to examine our early experience with TAVR in patients with QAV.

Materials and methods: Prospectively collected data were retrospectively reviewed in patients with QAV undergoing TAVR in our institution.

Results: Five patients with QAV and AR or AS were treated with TAVR between January 2016 and January 2022. The mean age was 73.8 years (range 69-82 years), and the median Society of Thoracic Surgeons score was 7.51% (range 2.668-18.138%). Two patients had type B and three had either type A, D, or F according to the Hurwitz and Roberts classification for QAV. Four patients with pure aortic regurgitation underwent transapical TAVR using the J-Valve system, and the patient with severe AS underwent transfemoral TAVR using the Venus-A system. Procedural success was achieved in all five patients. Trivial paravalvular leak was only detected in one case after the procedure, and one patient received a permanent pacemaker due to high-degree atrioventricular block three days later. The median follow-up period was 18 (12-56) months. After discharge, no deaths occurred during the 1 year follow-up. All patients improved by ≥1 New York Heart Association functional class at 30 days; four patients were in functional class ≤II later in the follow-up period. All patients' heart failure symptoms improved considerably.

Conclusion: Our early experience with TAVR in QAV demonstrates these procedures to be feasible with acceptable early results. Further follow-up is necessary to determine the long-term outcomes of this modality.

Clinical trial registration: [ClinicalTrials.gov], identifier [NCT02917980].

Keywords: aortic regurgitation; aortic stenosis; quadricuspid aortic valve; transcatheter; transcatheter aortic valve replacement.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Liu, Zhai, Mao, Xu, Ma, Li, Jin and Yang.

Figures

FIGURE 1
FIGURE 1
Anatomical structures of the quadricuspid aortic valves of five patients demonstrated with computed tomography angiography (CTA), 3-dimensional (3D) simulation, and 3D printing models.
FIGURE 2
FIGURE 2
Procedural details of transcatheter aortic valve replacement (TAVR) with the self-expandable J-Valve prosthesis in a patient with a quadricuspid aortic valve with pure aortic regurgitation. (A) 2-Dimensional transesophageal echocardiography (TEE) with color Doppler showed aortic regurgitation in the quadricuspid aortic valve before the procedure. (B) Preoperative angiography showed four sinuses and aortic regurgitation. (C) Postoperative angiography showed the final position of a 29 mm J-Valve prosthesis without a paravalvular leak after deployment. (D) 2-dimensional TEE with color Doppler showed no aortic regurgitation postprocedure.
FIGURE 3
FIGURE 3
Procedural details of transcatheter aortic valve replacement (TAVR) with the self-expandable Venus-A prosthesis in a patient with quadricuspid aortic valve with aortic stenosis (AS) and regurgitation. (A) 2-Dimensional transesophageal echocardiography (TEE) with color Doppler showed aortic regurgitation in the quadricuspid aortic valve before the procedure. (B) Angiography showed a satisfactory position of the THV prosthesis before deployment. (C) Angiography showed the final position of a 32 mm Venus-A prosthesis without a paravalvular leak after deployment. (D) 2-Dimensional TEE with color Doppler showed no aortic regurgitation postprocedure.
FIGURE 4
FIGURE 4
Hurwitz and Roberts classification of the quadricuspid aortic valve (QAV). (A) QAV with four equal-sized cusps. (B) QAV with three equal-sized cusps and one smaller cusp. (C) QAV with two equal larger cusps and two equal smaller cusps. (D) QAV with one larger cusp, two mid-sized cusps, and one smaller cusp. (E) QAV with one larger cusp and three equal-sized smaller cusps. (F) QAV with two equal-sized large cusps and two unequal smaller cusps. (G) QAV with four unequal-sized cusps.

References

    1. Tsang MYC, Abudiab MM, Ammash NM, Naqvi TZ, Edwards WD, Nkomo VT, et al. Quadricuspid aortic valve: characteristics, associated structural cardiovascular abnormalities, and clinical outcomes. Circulation. (2016) 133:312–9. 10.1161/CIRCULATIONAHA.115.017743
    1. Yuan SM. Quadricuspid aortic valve: a comprehensive review. Braz J Cardiovasc Surg. (2016) 31:454–60. 10.5935/1678-9741.20160090
    1. Perloff JK. The howard Gilman foundation lecture. Where have we come from and where are we going? Valve management past, present and future. Adv Cardiol. (2004) 41:1–8.
    1. Sohn J, Arain FD. Two consecutive cases of quadricuspid aortic valve and a review of 149 cases. J Cardiothorac Vasc Anesth. (2022) 36:717–23. 10.1053/j.jvca.2021.02.033
    1. Saith S, Saith S, Murthy A. Quadricuspid aortic valve: an introduction for clinicians. Cardiol Res. (2022) 13:2–10. 10.14740/cr1308
    1. Piracha UG, Kowlgi GN, Paulsen W, Mojadidi MK, Patel N. Quadricuspid aortic valve: a case report and review of literature. Future Cardiol. (2021) 17:833–40. 10.2217/fca-2020-0135
    1. Tsugu T, Murata M, Endo J, Kawakami T, Tsuruta H, Itabashi Y, et al. Long-term outcomes in 3 cases of quadricuspid aortic valve, using a new classification system: a case series and literature review. Echocardiography. (2019) 36:595–7. 10.1111/echo.14278
    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, III, Gentile F, et al. 2020 ACC/AHA guideline on the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. (2021) 143:e35–71. 10.1161/CIR.0000000000000960
    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. EuroIntervention. (2022) 17:e1126–96. 10.4244/EIJ-E-21-00009
    1. Zhou D, Fan J, Liu X, Wang JA. The first two cases of long-term outcomes after transcatheter aortic valve replacement in patients with quadricuspid aortic valve. J Invasive Cardiol. (2021) 33:E839–40.
    1. Fukui T, Kitabayashi K, Ogasawara N, Hasegawa S. Unequal quadricuspid aortic valve stenosis treated with transcatheter aortic valve replacement. Eur Heart J Case Rep. (2020) 4:1–2. 10.1093/ehjcr/ytaa314
    1. Benkemoun H, Bramlage P, Beaufigeau M. A four-leaf clover: a case report of quadricuspid aortic valve stenosis. J Card Surg. (2020) 35:1125–8. 10.1111/jocs.14511
    1. Aoyama R, Futami S, Tanaka J, Takeda K, Nishimura T, Tobaru T. Transcatheter aortic valve implantation using evolut R in quadricuspid aortic valve with severe stenosis and regurgitation. Cardiovasc Interv Ther. (2019) 34:285–7. 10.1007/s12928-018-0544-7
    1. Tohoku S, Shirai S, Hayashi M, Isotani A, Ando K. Successful transcatheter aortic valve implantation in a quadricuspid aortic valve with severe stenosis and moderate regurgitation. Cardiovasc Interv Ther. (2018) 33:400–1. 10.1007/s12928-017-0495-4
    1. Li L, Liu Y, Jin P, Tang J, Lu L, Zhu G, et al. Effect of eccentric calcification of an aortic valve on the implant depth of a venus-a prosthesis during transcatheter aortic valve replacement: a retrospective study. Front Physiol. (2021) 12:718065. 10.3389/fphys.2021.718065
    1. Liu H, Yang Y, Wang W, Zhu D, Wei L, Guo K, et al. Transapical transcatheter aortic valve replacement for aortic regurgitation with a second-generation heart valve. J Thorac Cardiovasc Surg. (2018) 156:106–16. 10.1016/j.jtcvs.2017.12.150
    1. Fei X, Elhmidi Y, Zhang B, Tang H, Zhu D, Chen Y, et al. Transapical transcatheter aortic valve implantation using a new TAVI system for high-risk patients with severe aortic stenosis. Heart Lung Circ. (2018) 27:e67–9. 10.1016/j.hlc.2017.07.007
    1. Liao YB, Zhao ZG, Wei X, Xu Y-N, Zuo Z-L, Li Y-J, et al. Transcatheter aortic valve implantation with the self-expandable venus A-valve and corevalve devices: preliminary experiences in China. Catheter Cardiovasc Interv. (2017) 89:528–33. 10.1002/ccd.26912
    1. Blanke P, Wengenmayer T, Sorg S, Pache G. Stenosed quadricuspid aortic valve treated by transcatheter aortic valve implantation. J Am Coll Cardiol. (2011) 57:1567. 10.1016/j.jacc.2010.06.065
    1. Han Y, Ribeiro JM, de Jaegere PPT, Zhang G. TAVR in a patient with quadricuspid aortic stenosis: the role of patient-specific computer simulation in treatment planning and outcome prediction. JACC Cardiovasc Interv. (2021) 14:e93–5. 10.1016/j.jcin.2021.01.014
    1. Luo C, Jiang Y, Chen Q, Yan Y, Han D. Trans-apical aortic valve implantation for quadricuspid aortic valve with aortic regurgitation using J-valve system: a case reports. J Cardiothorac Surg. (2021) 16:215. 10.1186/s13019-021-01586-9
    1. Takahashi M, Aizawa K, Oba Y, Funayama H, Kawahito K, Kario K. Should we protect the coronary artery during transcatheter aortic valve replacement in quadricuspid valve patients? JACC: Cardiovasc Interv. (2020) 13:1492–4. 10.1016/j.jcin.2020.03.014
    1. Ibrahim MKW, Barzallo M, Mungee S. Quadricuspid aortic valve stenosis: expanding our experience in transcatheter aortic valve implantation. J Invasive Cardiol. (2018) 30:E27.
    1. Sidharta S, Prakash R, Montarello J, Worthley S. Quadricuspid aortic valve stenosis treated with a novel, self-expanding, repositionable transcatheter aortic valve prosthesis. Int J Cardiol. (2015) 183:89–90. 10.1016/j.ijcard.2014.12.177
    1. Bruschi G, De Marco F, Klugmann S. Transcatheter valve implantation in a stenosed quadricuspid aortic valve. Asian Cardiovasc Thorac Ann. (2014) 22:627. 10.1177/0218492312475230
    1. Yu CW, Lee HJ. Quadricuspid aortic valve stenosis which caused multi-organ failure and was treated by transcatheter aortic valve implantation after balloon aortovalvuloplasty as a bridge therapy. EuroIntervention. (2014) 10:146. 10.4244/EIJV10I1A22
    1. Hurwitz LE, Roberts WC. Quadricuspid semilunar valve. Am J Cardiol. (1973) 31:623–6. 10.1016/0002-9149(73)90332-9
    1. Salemi A, Worku BM. Standard imaging techniques in transcatheter aortic valve replacement. J Thorac Dis. (2017) 9:S289–98. 10.21037/jtd.2017.03.114
    1. Tagliari AP, Petersen Saadi R, Medronha EF, Keller Saadi E. The use of BASILICA technique to prevent coronary obstruction in a TAVI-TAVI procedure. J Clin Med. (2021) 10:5534. 10.3390/jcm10235534
    1. Sultan I, Siki M, Wallen T, Szeto W, Vallabhajosyula P. Management of coronary obstruction following transcatheter aortic valve replacement. J Card Surg. (2017) 32:777–81. 10.1111/jocs.13252

Source: PubMed

3
구독하다